Company profile: Nascent Biotech
1.1 - Company Overview
Company description
- Provider of therapeutic antibodies and platform technologies. Pritumumab is a natural human IgG antibody targeting ecto-domain vimentin on adenocarcinomas, including brain cancers and melanoma; MultiPharm is a multi-agent (antibodies and/or cytokines) platform for potential treatment of cancer, diabetes, autoimmunity, and transplantation; and CLNH5 is a patented technology with four patents awarded by the United States Patent Office.
Products and services
- Pritumumab: Natural human IgG antibody targeting ecto-domain vimentin on the cell surface of various adenocarcinomas, including brain cancers and melanoma, for tumor-associated vimentin binding
- MultiPharm: Multi-agent platform technology using antibodies and/or cytokines for potential treatment of cancer, diabetes, autoimmunity, and transplantation, orchestrating combined therapeutic modalities across diverse disease contexts
- CLNH5: US-patent-backed technology with four patents awarded by the United States Patent Office, representing a patented asset within Nascent Biotech’s portfolio
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Nascent Biotech
Novavax
HQ: United States
Website
- Description: Provider of vaccines and vaccine technologies for infectious diseases, including a recombinant nanoparticle COVID-19 vaccine with Matrix-M adjuvant; a Phase 2 COVID-influenza combination (CIC) vaccine; and the authorized R21/Matrix-M malaria vaccine. Also offers Matrix-M, a saponin-based adjuvant, and recombinant nanoparticle vaccine technology using engineered proteins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novavax company profile →
Synaffix
HQ: The Netherlands
Website
- Description: Provider of a proprietary antibody-drug conjugate (ADC) technology platform enhancing efficacy and tolerability to treat cancer and other disorders, enabling development from any antibody. Offerings include GlycoConnect for stable ADCs, HydraSpace for improved payload performance, toxSYN linker-payloads, conversion of antibodies to bispecifics, and custom payload delivery (cytokines, TLR/STING agonists, oligonucleotides, peptides, antibiotics, cytotoxics).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synaffix company profile →
Akari Therapeutics
HQ: United Kingdom
Website
- Description: Provider of clinical-stage therapeutics focused on development and commercialization of innovative treatments, including nomacopan, a bispecific recombinant inhibitor targeting complement C5 and LTB4 for autoimmune and inflammatory diseases; a Phase 3 HSCT-TMA program for pediatric and adult transplant-related thrombotic microangiopathy; and PAS-nomacopan, a long-acting candidate for geographic atrophy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Akari Therapeutics company profile →
Bright Peak Therapeutics
HQ: Switzerland
Website
- Description: Provider of immunotherapies for cancer and autoimmune diseases, enabling tissue- and cell-specific cytokine targeting with enhanced efficacy. Offerings include Bright Peak Immunoconjugates combining optimized cytokines with antibodies; a chemical protein synthesis platform for novel proteins; and candidates such as BPT567 (PD1-IL18), BPT331 (PD1-IL2), and BPT331CAPS (PD1-IL2CAPS).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bright Peak Therapeutics company profile →
Trillium Therapeutics
HQ: Canada
Website
- Description: Provider of biopharmaceutical research and development focused on immune system regulation and the discovery and development of protein therapeutics—including monoclonal antibodies, secreted proteins, and peptides—for cancer and autoimmune indications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trillium Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Nascent Biotech
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Nascent Biotech
2.2 - Growth funds investing in similar companies to Nascent Biotech
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Nascent Biotech
4.2 - Public trading comparable groups for Nascent Biotech
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →